Journal
EXPERIMENTAL DERMATOLOGY
Volume 19, Issue 8, Pages E299-E301Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1600-0625.2009.00995.x
Keywords
bexarotene; cutaneous T-cell lymphoma; keratinocytes; Langerhans cells
Categories
Funding
- Cephalon Laboratories
- 'CIC centre d'investigation clinique de biotherapies de Nantes'
Ask authors/readers for more resources
There are several approved therapies for cutaneous T-cell lymphoma (CTCL). The retinoids are one of the major biologic response modifiers used in CTCL, producing good response rates but few complete responses. Bexarotene has been demonstrated to act on malignant T-cells by inducing their apoptosis, but nothing is known about its role on keratinocytes and Langerhans cells. Immunohistochemical analysis using CD1a, HLA-DR, ICAM-1 (activation markers), CD95 and CD40 (apoptosis markers) was conducted on frozen sections of bexarotene-exposed cutaneous explants and skin biopsy specimens from patients treated with bexarotene. None of the studied markers was significantly modulated both on cutaneous explants and on skin biopsy specimens after treatment with bexarotene, compared to controls. Langerhans cells and keratinocytes do not appear to play a central role in the therapeutic control of CTCL by bexarotene therapy. The main bexarotene's target thus remains T-cells by inducing their apoptosis, a mechanism that is different from the other retinoids used in CTCL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available